膀胱癌患者术后行吡柔比星与吉西他滨膀胱灌注化疗的疗效分析

Effect of pirarubicin and gemcitabine intravesical chemotherapy on the recurrence and postoperative survival of bladder cancer patients

目的探讨膀胱癌患者术后应用吡柔比星和吉西他滨膀胱灌注化疗对改善术后复发及生存期的影响。方法选取2011年2月至2013年5月间大连大学附属中山医院收治的78例膀胱癌行保留膀胱术患者,按照随机抽签法将患者分为观察组和对照组,每组39例。观察组患者术后即刻向膀胱内灌注吉西他滨;对照组患者术后即刻向膀胱内灌注吡柔比星。观察比较两组患者治疗期间的不良反应率,并统计随访2年患者生存及复发人数。结果术后2年,两组患者均全部生存,生存率为100.0%。观察组患者复发率为23.1%,对照组为25.6%,两组比较差异无统计学意义(P>0.05)。观察组患者治疗期间不良反应发生率为12.8%,明显低于对照组的30.8%,差异有统计学意义(P<0.05)。结论与对照组比较,观察组患者临床效果显著,且不良反应少,可减轻患者痛苦,值得推广。

Objective To explore the effect of pirarubicin and gemcitabine and intravesical chemotherapy on the recurrence and postoperative survival of bladder cancer patients. Methods From February 2011 to May 2013 in Dalian University Affiliated Zhongshan Hospital, 78 cases of bladder cancer were selected and devided to observation group and control group, with 39 cases in each group. Patients in observation group were received immediate postoperative instillation of gemcitabine to bladder; while patients in control group were received immediate postoperative instillation of pirarubicin to bladder. The rate of adverse reactions during treatment were compared in the two groups. After 2 years of follow-up, the number of survival and recurrence cases were recorded. Results After 2 years, patients in two groups were all survival, and survival rate was 100. 0%. Recurrence rate of patients in the observation group was 23.1% , which was 25.6% in the control group, and the difference had no statistical significance （ P 〉 0.05 ）. Adverse reaction rate of patients in the treatment group was 12. 8%, which was significantly lower than that in the control group （30. 8% 0, and the difference was statistically significant （P 〈 0.05 ）. Conclusions Compared with pirarubicin, the application of gemcitabine chemotherapy treatment in patients with bladder cancer have a significant effect, but which produce fewer adverse reactions, and therefore reduce the suffering of patients. It is worth clinical promotion.